Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28263864 | 0.87 | CYP19A1 (0.68) | CYP19A1CCR1CCR2PTGDR2ADRA1A | |
| SCHEMBL1806234 | 0.79 | CYP11B1 (0.54) | CYP19A1CCR1CCR2PTGDR2ADRA1A | |
| SCHEMBL6712996 | 0.79 | CYP19A1 (0.58) | CYP19A1CCR1CCR2PTGDR2ADRA1A | |
| SCHEMBL11128645 | 0.79 | CYP19A1 (0.70) | CYP19A1TYRCCR1CCR2 | |
| SCHEMBL8801557 | 0.79 | CYP19A1 (0.58) | CYP19A1CCR1CCR2PTGDR2ADRA1A | |
| SCHEMBL29820003 | 0.79 | CYP19A1 (0.70) | CYP19A1CCR1CCR2CYP2A13 | |
| SCHEMBL9125316 | 0.79 | CYP19A1 (0.58) | CYP19A1CCR1CCR2CYP2A13PTGDR2 | |
| SCHEMBL10603653 | 0.77 | CYP19A1 (0.56) | CYP19A1CCR1CCR2PTGDR2 | |
| SCHEMBL16050772 | 0.76 | CYP19A1 (0.59) | CYP19A1CCR1CCR2PTGDR2 | |
| SCHEMBL7823323 | 0.75 | TYR (0.43) | TYRCYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119101052-A | Matrine-triazole derivative and synthesis method thereof | 吉林医药学院 | 2024-12-10 | — | — | CN | disclosed |
| CN-114957222-B | Compound and preparation method and application thereof | 内蒙古民族大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-114957222-A | Compound and preparation method and application thereof | 内蒙古民族大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-3998258-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL- 1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3- (METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | Merck Sharp & Dohme Corp. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3233824-B1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3- (METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3233079-B1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11034673-B2 | (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | MERCK SHARP & DOHME CORP. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200299266-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710982-B2 | (S)-N-(3-6-isopropoxypyridin-3-3YL)-1H-indazol-5-yl)-1-(2-(4-4(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H-yl)-2-oxoethyl)-3(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | MERCK SHARP & DOHME CORP. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200181119-A1 | (S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20180000803-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170362202-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3233824-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3- (METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233079-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017040362-A1 | PROCESS FOR PREPARING SPRAY DRIED SOLID DISPERSIONS OF (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3- (METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016100152-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100147-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3- (METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2013010880-A1 | NEW CRTH2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362202-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HINT1 | CYP19A1 4237/4885TYR 2578/4885CCR1 3433/4885 |
| US-20180000803-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | S100P, TSLP, TPSAB1 | CYP19A1 2560/4885TYR 86/4885CCR1 3401/4885 |
| US-20200181119-A1 | (S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | HK1, HINT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP19A1 4259/4885TYR 2239/4885CCR1 4048/4885 |
| US-20200299266-A1 | (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, HINT1 | CYP19A1 4187/4885TYR 2263/4885CCR1 3984/4885 |
| US-10710982-B2 | (S)-N-(3-6-isopropoxypyridin-3-3YL)-1H-indazol-5-yl)-1-(2-(4-4(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H-yl)-2-oxoethyl)-3(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | HK1, HINT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP19A1 4259/4885TYR 2239/4885CCR1 4048/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885TYR 562/4885CCR1 409/4885 |
| US-11034673-B2 | (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, HINT1 | CYP19A1 4146/4885TYR 2254/4885CCR1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.